Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SMAD2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SMAD2 Recombinant Protein (Full-Length & Domain-Specific) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for interaction assays and kinase substrates. |
View SMAD2 Products |
| Gene Delivery | SMAD2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View SMAD2 Products |
| Benchmark Ab | Anti-SMAD2 Recombinant Antibody Sequence-derived monoclonal antibody for positive control in Western Blot, ELISA, and IP. |
View SMAD2 Products |
| Validator | SMAD2 siRNA Set Target-specific siRNA pool for knockdown verification and functional rescue assays. |
View SMAD2 Products |
| Related Target A | TGFBR1 Upstream kinase (ALK5) that phosphorylates SMAD2; critical for in vitro phosphorylation assays. |
View TGFBR1 Products |
| Related Target B | SMAD3 Highly homologous sister R-SMAD; essential for selectivity and off-target profiling. |
View SMAD3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing SMAD2 from SMAD3 (High Homology) | Sequence-verified proteins with strict mass spectrometry quality control to ensure sequence identity. |
| Phosphorylation-State Analysis (p-SMAD2) | High-purity unphosphorylated SMAD2 substrate coupled with active TGFBR1 kinase for robust in vitro phosphorylation assays. |
| Lack of Controls | Recombinant benchmark antibodies and validated siRNA sets included in the assay development suite. |
| False Positives in Cellular Screening | Lentivirus-driven stable expression and siRNA knockdown dual-system validation. |
Live SMAD2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SMAD2 therapeutics is intensifying, with major players shifting focus from traditional TGF-beta ligand traps to intracellular targeted protein degraders (PROTACs/molecular glues) and selective small-molecule inhibitors. As first-generation systemic TGF-beta inhibitors face clinical limitations due to cardiotoxicity and pleiotropic side effects, the next wave of R&D is targeting intracellular nodes like SMAD2 to achieve pathway-specific, tissue-selective therapeutic outcomes in severe fibrosis and immunologically "cold" tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Arvinas, C4 Therapeutics | Solid Tumors, Idiopathic Pulmonary Fibrosis (IPF) | Degradation kinetics and ternary complex validation (Need high-purity full-length SMAD2 and SMAD3 for selectivity assays) |
| Small Molecule PPI Inhibitor | Novartis, Eli Lilly | Oncology, Renal Fibrosis | Protein-protein interaction screening (Need SMAD2-SMAD4 complex assembly assays) |
| siRNA / RNAi | Alnylam Pharmaceuticals | Hepatic Fibrosis, NASH | Target knockdown efficiency and duration of response (Need validated siRNA and Lentivirus for stable reporter lines) |